Brind.

Emerging competition from Roche is a near-term concern for Illumina.

1 report, 0 independent Updated Jun 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Illumina Hoffmann-La Roche

Keep exploring

The entities involved

Illumina
American company that develops systems for the analysis of genetic variation
- Analysis suggests that both Moderna and Illumina stocks are currently overvalued.Wed 13:01
Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08

Coverage

Newest first; wire copies grouped

Jun 25Unknown outlet